Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DU]) in patients with glioblastoma (GBM): results for cohort B (DUR monotherapy), bevacizumab naive patients with recurrent GBM - Reardon, D A; Kaley, T; Dietrich, J
Paper presented at: 21st Annual Meeting of the Society for Neuro-Oncology2016; Scottsdale, Arizona